文献速递肾癌与肾肿瘤

通过全面基因组分析表征晚期乳头状肾细胞癌临床病例

Characterization of Clinical Cases of Advanced Papillary Renal Cell Carcinoma via Comprehensive Genomic Profiling.
PubMed 文献 · Eur Urol · 2017-06-04

本研究对169例确诊乳头状肾细胞癌(PRCC)患者的石蜡包埋组织进行中央实验室全面基因组分析,中位测序深度648×。结果显示1型PRCC常见MET(33%)、TERT(30%)、CDKN2A/B(13%)和EGFR(8%)改变,2型常见CDKN2A/B(18%)、TERT(18%)、NF2(13%)和FH(13%)改变,MET改变见于7%的2型病例。作者认为这些结果可能为转移性PRCC的精准医学试验提供信息。

要点

  • 1型PRCC常见改变为MET(33%)、TERT(30%)、CDKN2A/B(13%)和EGFR(8%)。
  • 2型PRCC常见改变为CDKN2A/B(18%)、TERT(18%)、NF2(13%)和FH(13%),MET改变占7%。
  • 与TCGA数据相比,MET、NF2和CDKN2A/B改变频率更高,SWI/SNF复合物基因改变与2型PRCC相关。

核心结论

  • 当前研究与TCGA经验代表样本量相近的PRCC患者队列,基因改变频率的关键差异可能解释两个数据集之间分期分布的显著不同。
  • 这些结果可能为计划中的转移性PRCC精准医学试验提供信息。

研究设计与样本

  • 对169例连续确诊PRCC患者的福尔马林固定石蜡包埋组织进行DNA提取,并在认证的中央实验室进行全面基因组分析。
  • 采用杂交捕获、接头连接文库对最多315个基因进行测序,中位覆盖度为648×,识别包括替换、插入/缺失、拷贝数改变和重排在内的所有类型基因改变。

主要发现

  • 169例患者中,收集原发肿瘤组织者102例(60%),转移灶组织者67例(40%)。
  • 1型PRCC中常见改变基因为MET(33%;8个激活突变,5个拷贝数>6的扩增)、TERT(30%)、CDKN2A/B(13%)和EGFR(8%)。
  • 2型PRCC中常见改变基因为CDKN2A/B(18%)、TERT(18%)、NF2(13%)和FH(13%);MET基因改变(5个突变,3个扩增)见于7%的2型病例。
  • 与TCGA数据相比,MET、NF2和CDKN2A/B基因改变频率更高,SWI/SNF复合物基因改变与2型PRCC相关,且1型和2型PRCC中均观察到频繁的CDKN2A/B改变。

临床怎么用

  • 作者认为这些结果可能为计划中的转移性PRCC精准医学试验提供信息。
  • 作者指出本报告突出了PRCC的一些独特生物学特征,可能为未来靶向治疗转移性疾病的用途提供信息。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Papillary renal cell carcinoma (PRCC) is a rare subset of RCC. The Cancer Genome Atlas (TCGA) data largely reflect localized disease, and there are limited data for advanced PRCC. OBJECTIVE: To characterize the frequency of genomic alterations (GAs) in patients with advanced PRCC for whom comprehensive genomic profiling (CGP) was performed in the context of routine clinical care. DESIGN, SETTING, AND PARTICIPANTS: Formalin-fixed, paraffin-embedded tissue was obtained for 169 consecutive patients with confirmed PRCC. DNA was extracted and comprehensive genomic profiling was performed in a certified central laboratory. MEASUREMENTS: Hybrid-capture, adaptor ligation-based libraries of up to 315 genes were sequenced to a median coverage of 648×. All classes of GAs were identified, including substitutions, insertions/deletions, copy number alterations, and rearrangements. RESULTS AND LIMITATIONS: From 169 patients, either primary tumor tissue (102 patients, 60%) or metastatic tissue (67 patients, 40%) was collected. In patients with type 1 PRCC, commonly altered genes were MET (33%; 8 activating mutations, 5 amplifications at >6 copies), TERT (30%), CDKN2A/B (13%), and EGFR (8%). In patients with type 2 PRCC, commonly altered genes were CDKN2A/B (18%), TERT (18%), NF2 (13%), and FH (13%); MET GAs (5 mutations, 3 amplifications) were observed in 7% of type 2 cases. Notable differences from TCGA data include higher frequencies of MET, NF2, and CDKN2A/B GAs, association of alterations in SWI/SNF complex genes with type 2 PRCC, and observation of frequent CDKN2A/B alterations in both type 1 and type 2 disease. CONCLUSIONS: Both the current study and the TCGA experience represent similarly sized cohorts of patients with PRCC. Key differences in GA frequency probably underscore the marked difference in stage distribution between these data sets. These results may inform planned precision medicine trials for metastatic PRCC. PATIENT SUMMARY: Papillary renal cell carcinoma (PRCC) is a rare subtype of kidney cancer, and understanding of the biology of advanced PRCC is limited. This report highlights some of the unique biologic features of PRCC that may inform on future use of targeted therapies for the treatment of metastatic disease.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Pal SK, Ali SM, Yakirevich E, et al. Characterization of Clinical Cases of Advanced Papillary Renal Cell Carcinoma via Comprehensive Genomic Profiling. Eur Urol. 2017. PMID: 28592388. doi:10.1016/j.eururo.2017.05.033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。